SCM
GILD icon

SCS Capital Management’s Gilead Sciences GILD Stock Holding History

SCS Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$915K Sell
6,563
-542
-8% -$75.9K 0.01% 286
2025
Q4 		$872K Sell
7,105
-4
-0.1% -$486 0.01% 297
2025
Q3 		$789K Sell
7,109
-506
-7% -$57.5K 0.01% 312
2025
Q2 		$844K Buy
7,615
+7
+0.1% +$745 0.01% 310
2025
Q1 		$853K Buy
+7,608
New +$785K 0.01% 279

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCS Capital Management's GILD Position: Q1 2026 in Review

SCS Capital Management reduced its Gilead Sciences (GILD) stake by 7.6% in Q1 2026, selling an estimated $75.9K and leaving 6,563 shares worth $915K. The position accounts for 0.01% of the portfolio, ranked #286.

SCS Capital Management first reported a position in GILD in Q1 2025 and has held it in 5 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • SCS Capital Management held 6,563 shares of Gilead Sciences worth $915K as of Q1 2026.
  • SCS Capital Management sold 542 Gilead Sciences shares in Q1 2026, an estimated $75.9K.
  • Gilead Sciences made up 0.01% of SCS Capital Management's portfolio in Q1 2026, its #286 holding.
  • SCS Capital Management first reported a position in Gilead Sciences in Q1 2025 and has held it in 5 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.